US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
Read More
